Did you know ? If you order before Friday 14h we deliver 90PCT of the the time next Tuesday, GENTAUR another in time delivery

Pubmed ID :28904172
Publication Date : 2017/09/14

FDA Approval Summary: Daratumumab for Treatment of Multiple Myeloma After One Prior Therapy.


On November 21, 2016, the U.S. Food and Drug Administration granted regular approval to daratumumab in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy. Approval was based on two randomized, open-label trials in which daratumumab was added to these backbone therapies. The MMY3003 trial demonstrated substantial improvement in progression-free survival (PFS) when daratumumab was added to lenalidomide and dexamethasone compared with lenalidomide and dexamethasone alone. The estimated median PFS had not been reached in the daratumumab arm and was 18.4 months in the control arm (hazard ratio [HR] = 0.37; 95% confidence interval [CI]: 0.27-0.52; p < .0001), representing a 63% reduction in the risk of disease progression or death. Similar results were observed in the MMY3004 trial comparing the combination of daratumumab, bortezomib, and dexamethasone with bortezomib and dexamethasone. The estimated median PFS was not reached in the daratumumab arm and was 7.2 months in the control arm (HR = 0.39; 95% CI: 0.28-0.53; p < .0001), representing a 61% reduction in the risk of disease progression or death. The most frequently reported adverse reactions (greater than or equal to 20%) in MMY3003 were infusion reactions, diarrhea, nausea, fatigue, pyrexia, upper respiratory tract infection, muscle spasm, cough, and dyspnea. The most frequently reported adverse reactions (greater than or equal to 20%) in MMY3004 were infusion reactions, diarrhea, peripheral edema, upper respiratory tract infection, and peripheral sensory neuropathy. Neutropenia and thrombocytopenia have been added to the Warnings and Precautions of the drug label.

Authors : Bhatnagar Vishal , Gormley Nicole J , Luo Lola , Shen Yuan Li , Sridhara Rajeshwari , Subramaniam Sriram , Shen Guoxiang , Ma Lian , Shord Stacy , Goldberg Kirsten B , Farrell Ann T , McKee Amy E , Pazdur Richard ,

Related products :

Catalog number Product name Quantity
EIAAB25945 Homo sapiens,Human,Myeloma-overexpressed gene protein,MYEOV,OCIM,Oncogene in multiple myeloma
27-424 Altered expression of GBX2, part of the homeobox-containing human family of DNA-binding transcription factors, is associated with therapy failure and death in patients with multiple types of cancer. 0.1 mg
1861 Normal rat multiple organ frozen tissue array, for therapeutic and diagnostic antibody validation for FDA approval, 45 cases_45 cores, slide 2 of 2 tissue arrays, replacing FRA901-1
1862 Normal rat multiple organ frozen tissue array, for therapeutic and diagnostic antibody validation for FDA approval, 45 cases_45 cores, slide 2 of 2 tissue arrays, replacing FRA901-2
FRA901a-2 Normal rat multiple organ frozen tissue array, for therapeutic and diagnostic antibody validation for FDA approval, 45 cases_45 cores, slide 2 of 2 tissue arrays, replacing FRA901-2; ihc Anti-Actin c
FRA901a-1 Normal rat multiple organ frozen tissue array, for therapeutic and diagnostic antibody validation for FDA approval, 45 cases_45 cores, slide 2 of 2 tissue arrays, replacing FRA901-1; ihc Anti-Actin c
DMMI-123-V Human Sample (Multiple Myeloma), individual 1
DMMI-123-X Human Sample (Multiple Myeloma), individual 1 ml
DMMI-123-V Human Sample (Multiple Myeloma), Individual 1unit
DMMI-123-X Human Sample (Multiple Myeloma), Individual 1ml
TRIB1_MOUSE Mouse ELISA Kit FOR Multiple myeloma tumor-associated protein 2 homolog 96T
E0197r Mouse ELISA Kit FOR Multiple myeloma tumor-associated protein 2 homolog 96T
EPHA7_HUMAN Mouse ELISA Kit FOR Multiple myeloma tumor-associated protein 2 homolog 96T
CSB-EL003593HU Human Multiple myeloma tumor-associated protein 2(C1orf35) ELISA kit 96T
orb61232 Carfilzomib Carfilzomib was discovered and advanced to multiple Phase 1 and 2 clinical trials, including a pivotal Phase 2 clinical trial designed to seek accelerated approval, by Proteolix, Inc. For 5 mg
EIAAB25041 Mmtag2,Multiple myeloma tumor-associated protein 2 homolog,Rat,Rattus norvegicus
EIAAB25040 Bos taurus,Bovine,MMTAG2,Multiple myeloma tumor-associated protein 2 homolog
CSB-EL003593HU Human Multiple myeloma tumor-associated protein 2(C1orf35) ELISA kit SpeciesHuman 96T
MYF5 MYEOV Gene myeloma overexpressed (in a subset of t(11;14) positive multiple myelomas)
EIAAB25042 Mmtag2,Mouse,Multiple myeloma tumor-associated protein 2 homolog,Mus musculus
MMTA2_RAT ELISA Kit FOR Multiple myeloma tumor-associated protein 2 homolog; organism: Rat; gene name: Mmtag2 96T
NHL401 Lymphoma, multiple myeloma and lymph node tissue array, 40 cases_40 cores
ACYTCSMM Cycloscope MM, immunophenotypically identify plasma cells or Monoclonal Gammopathies in Multiple Myeloma
201-20-3575 MYEOV{myeloma overexpressed gene (in a subset of t(11 ; 14) positive multiple myelomas)}rabbit.pAb 0.2ml
MMTA2_MOUSE ELISA Kit FOR Multiple myeloma tumor-associated protein 2 homolog; organism: Mouse; gene name: Mmtag2 96T


 

GENTAUR Belgium BVBA BE0473327336
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45

Fax 0032 16 50 90 45
info@gentaur.com | Gentaur





GENTAUR Ltd.
Howard Frank Turnberry House
1404-1410 High Road
Whetstone London N20 9BH
Tel 020 3393 8531 Fax 020 8445 9411
uk@gentaur.com | Gentaur

 

 




GENTAUR France SARL
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50

Fax 01 43 25 01 60
RCS Paris B 484 237 888

SIRET 48423788800017

BNP PARIBAS PARIS PL MAUBERT BIC BNPAFRPPPRG

france@gentaur.com | Gentaur

GENTAUR GmbH
Marienbongard 20
52062 Aachen Deutschland
Support Karolina Elandt
Tel: 0035929830070
Fax: (+49) 241 56 00 47 88

Logistic :0241 40 08 90 86
Bankleitzahl 39050000
IBAN lautet DE8839050000107569353
Handelsregister Aachen HR B 16058
Umsatzsteuer-Identifikationsnummer *** DE 815175831
Steuernummer 201/5961/3925
de@gentaur.com | Gentaur

GENTAUR U.S.A
Genprice Inc, Logistics
547, Yurok Circle
San Jose, CA 95123
CA 95123
Tel (408) 780-0908,
Fax (408) 780-0908,
sales@genprice.com

Genprice Inc, Invoices and accounting
6017 Snell Ave, Ste 357
San Jose, CA 95123




GENTAUR Nederland BV
NL850396268B01 KVK nummer 52327027
Kuiper 1
5521 DG Eersel Nederland
Tel:  0208-080893  Fax: 0497-517897
nl@gentaur.com | Gentaur
IBAN: NL04 RABO 0156 9854 62   SWIFT RABONL2U






GENTAUR Spain
tel:0911876558
spain@gentaur.com | Gentaur






ГЕНТАУЪР БЪЛГАРИЯ
ID # 201 358 931 /BULSTAT
София 1000, ул. "Граф Игнатиев" 53 вх. В, ет. 2
Tel 0035924682280 Fax 0035924808322
e-mail: Sofia@gentaur.com | Gentaur
IBAN: BG11FINV91501014771636
BIC: FINVBGSF

GENTAUR Poland Sp. z o.o.


ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
TEL Gdansk 058 710 33 44 FAX  058 710 33 48              

poland@gentaur.com | Gentaur

Other countries

Österreich +43720880899

Canada Montreal +15149077481

Ceská republika Praha +420246019719

Danmark +4569918806

Finland Helsset +358942419041

Magyarország Budapest +3619980547

Ireland Dublin+35316526556

Luxembourg+35220880274

Norge Oslo+4721031366

Sverige Stockholm+46852503438

Schweiz Züri+41435006251

US New York+17185132983

GENTAUR Italy
SRL IVA IT03841300167
Piazza Giacomo Matteotti, 6
24122 Bergamo Tel 02 36 00 65 93
Fax 02 36 00 65 94
italia@gentaur.com | Gentaur